Salarius Pharmaceuticals Inc (SLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has a cash flow conversion efficiency ratio of -0.388x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($4.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SLRX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Salarius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Salarius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
-0.151x |
|
Proactis SA
PA:PROAC
|
1.580x |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
0.000x |
|
Duksung Co Ltd
KO:004835
|
0.003x |
|
Pacific Strategic Financial
JK:APIC
|
-0.063x |
|
Anglo Asian Mining Plc
LSE:AAZ
|
0.159x |
|
DomaCom Limited
AU:DCL
|
0.000x |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Salarius Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Salarius Pharmaceuticals Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Salarius Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -- |
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more